KC7F2

927822-86-4

C16H16Cl4N2O4S4

DMSO : >= 32 mg/mL (56.10 mM)

Metabolic Enzyme/Protease

KC7F2 is a potent hypoxia inducible factor-1 (HIF-1) pathway inhibitor with an IC₅₀ of 20 uM in LN229-HRE-AP cells, and with potential as a cancer therapy agent^[1]. IC50 & Target: IC50: 20 uM (HIF-1, LN229-HRE-AP cells)^[1] In Vitro: KC7F2 (15–25 uM; 0-72 hours) exhibits a clear dose-response cytotoxicity with an IC₅₀ value of approximately 15–25 uM depending on the cell lines, and this effect is more severe under hypoxic conditions^[1].
KC7F2 (0-80 uM; 6 hours) specifically reduces the protein levels of HIF-1alpha in a dose-dependent manner under hypoxic conditions; strongly decrease in HIF-1alpha levels at concentrations above 20 uM^[1].
KC7F2 does not affect the rate of HIF-1alpha protein degradation^[1].
KC7F2 inhibits HIF-1alpha protein synthesis but not its mRNA transcription^[1].
KC7F2 represses the phosphorylation of eukaryotic initiation factor 4E binding protein 1 (4EBP1)^[1].